Benzinga | Aug 6, 2021 08:44AM EDT

Canaccord Genuity Downgrades Neurocrine Biosciences to Hold, Lowers Price Target to $108

Canaccord Genuity analyst Sumant Kulkarni downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Buy to Hold and lowers the price target from $122 to $108.